Bortezomib promotes the TRAIL-mediated killing of resistant rhabdomyosarcoma by ErbB2/Her2-targeted CAR-NK-92 cells via DR5 upregulation

Treatment resistance and immune escape are hallmarks of metastatic rhabdomyosarcoma (RMS), underscoring the urgent medical need for therapeutic agents against this disease entity as a key challenge in pediatric oncology. Chimeric antigen receptor (CAR)-based immunotherapies, such as the ErbB2 (Her2)...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Catrin Heim, Leonie Hartig, Nadine Weinelt, Laura M. Moser, Emilia Salzmann-Manrique, Michael Merker, Winfried S. Wels, Torsten Tonn, Peter Bader, Jan-Henning Klusmann, Sjoerd J.L. van Wijk, Eva Rettinger
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Elsevier 2024-06-01
Edice:	Molecular Therapy: Oncology
Témata:	MT: Regular Issue chimeric antigen receptor immunotherapy bortezomib TRAIL rhabdomyosarcoma
On-line přístup:	http://www.sciencedirect.com/science/article/pii/S2950329924000444
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!